Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
| Autor: | Xiaochun Yang, Peihua Luo, Hao Yan, Qiaojun He, Leilei Ai, Jian Chen, Zhifei Xu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.medical_specialty biology business.industry Immune checkpoint inhibitors Cancer therapy Pharmaceutical Science Cancer medicine.disease Clinical trial 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis PD-L1 Drug Discovery medicine biology.protein Intensive care medicine business Adverse effect |
| Zdroj: | Drug Design, Development and Therapy. 14:3625-3649 |
| ISSN: | 1177-8881 |
| DOI: | 10.2147/dddt.s267433 |
| Popis: | PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. However, the serious immune-related adverse reactions limited the clinical application of PD-1/PD-L1 monoclonal antibodies, despite the promising curative effects. Therefore, it is urgent to develop novel inhibitors, such as small molecules, peptides or macrocycles, targeting the PD-1/PD-L1 axis to meet the increasing clinical demands. Our review discussed the mechanism of action of PD-1/PD-L1 inhibitors and presented clinical trials of currently approved PD-1/PD-L1 targeted drugs and the incidence of related adverse reactions, helping clinicians pay more attention to them, better formulate their intervention and resolution strategies. At last, some new inhibitors whose patent have been published are listed, which provide development ideas and judgment basis for the efficacy and safety of novel PD-1/PD-L1 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|